Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.
News|Videos|June 26, 2025
Combination Treatment With Novel BCL2 Inhibitor Sonrotoclax (BGB-11417) and Zanubrutinib Induces High Rate of Complete Remission for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Author(s)Raul Cordoba, MD, PhD
Raul Cordoba, MD, PhD, presents results from the phase 1 study of sonrotoclax plus zanubrutinib in relapsed/refractory mantle cell lymphoma, highlighting a favorable safety profile with no tumor lysis syndrome or atrial fibrillation, and promising antitumor activity, including a 78% overall response rate and a 70% complete response rate at the recommended dose of 320 mg.
Advertisement
Advertisement
Related to this article
Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.
Relacorilant plus nab-paclitaxel and bevacizumab produced a 59% response rate in platinum-resistant ovarian cancer in Part A of the BELLA trial.
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.
Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
4
Phase 3 IMpactMF Trial Evaluating Imetelstat in R/R Myelofibrosis Is Discontinued
5